Discovering Associations of Adverse Events with Pharmacotherapy in Patients with Non-Small Cell Lung Cancer Using Modified Apriori Algorithm

<table class="fixed-width table-group" id="tab3"><tr><td><table class="table"><colgroup><col style="width:7.96em"/><col style="width:10.19em"/><col style="width:12.42em"/></colgroup><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Agents</td><td class="align_center">Number of patients</td><td class="align_center">Percentage of patients treated with molecular targeted drugs</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Rh-endostatin</td><td class="align_center">242</td><td class="align_center">28.01%</td></tr><tr><td class="align_left">Bevacizumab</td><td class="align_center">233</td><td class="align_center">26.97%</td></tr><tr><td class="align_left">Gefitinib</td><td class="align_center">130</td><td class="align_center">15.05%</td></tr><tr><td class="align_left">Erlotinib</td><td class="align_center">74</td><td class="align_center">8.56%</td></tr><tr><td class="align_left">Icotinib</td><td class="align_center">63</td><td class="align_center">7.29%</td></tr><tr><td class="align_left">Nimotuzumab</td><td class="align_center">53</td><td class="align_center">6.13%</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Targeted drugs used in treatment.</div>

BioMed Research International

tab3

Table 3

Table 3: Discovering Associations of Adverse Events with Pharmacotherapy in Patients with Non-Small Cell Lung Cancer Using Modified Apriori Algorithm 

Table 3 | Discovering Associations of Adverse Events with Pharmacotherapy in Patients with Non-Small Cell Lung Cancer Using Modified Apriori Algorithm 